Based on peripheral blood plasma specimens from 40 GC patients received HER2-targeted therapy, the dynamic surveillance of plasma ctDNA genomic features provided instructive information for determining the effeteness of this targeted drug (59). The gene discussed is ERBB2; the disease is gastric cancer.